IRIS
AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.706
AS - Asia 8.126
EU - Europa 2.272
SA - Sud America 1.475
AF - Africa 412
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 8
Totale 25.018
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.466
SG - Singapore 5.226
BR - Brasile 1.220
CN - Cina 1.155
VN - Vietnam 782
FI - Finlandia 445
IE - Irlanda 324
IT - Italia 277
NG - Nigeria 272
DE - Germania 262
HK - Hong Kong 237
FR - Francia 191
GB - Regno Unito 181
IN - India 159
CA - Canada 144
NL - Olanda 137
SE - Svezia 109
AR - Argentina 106
RU - Federazione Russa 83
TR - Turchia 72
BD - Bangladesh 69
MX - Messico 55
IQ - Iraq 54
IL - Israele 49
BE - Belgio 44
ID - Indonesia 43
UA - Ucraina 39
EC - Ecuador 34
JP - Giappone 34
PK - Pakistan 34
EG - Egitto 31
PL - Polonia 31
CO - Colombia 30
PH - Filippine 30
ZA - Sudafrica 30
ES - Italia 29
VE - Venezuela 26
KE - Kenya 21
MK - Macedonia 20
IR - Iran 19
JO - Giordania 19
UZ - Uzbekistan 19
CL - Cile 17
PY - Paraguay 16
AU - Australia 15
MA - Marocco 15
DZ - Algeria 14
NP - Nepal 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 12
PE - Perù 11
AE - Emirati Arabi Uniti 10
AL - Albania 10
AZ - Azerbaigian 10
KR - Corea 10
MY - Malesia 10
RO - Romania 10
AT - Austria 8
CH - Svizzera 8
JM - Giamaica 8
KZ - Kazakistan 8
LT - Lituania 8
TN - Tunisia 8
UY - Uruguay 8
ET - Etiopia 7
GR - Grecia 7
OM - Oman 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DO - Repubblica Dominicana 6
LB - Libano 6
PA - Panama 6
RS - Serbia 6
BG - Bulgaria 5
TW - Taiwan 5
HN - Honduras 4
LV - Lettonia 4
MD - Moldavia 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
CR - Costa Rica 3
HU - Ungheria 3
KW - Kuwait 3
MN - Mongolia 3
NI - Nicaragua 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
TH - Thailandia 3
AM - Armenia 2
BB - Barbados 2
BS - Bahamas 2
BW - Botswana 2
EE - Estonia 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LY - Libia 2
PT - Portogallo 2
SN - Senegal 2
Totale 24.985
Salva come PNG Salva come JPEG
Città #
Singapore 2.497
Chandler 1.920
Wilmington 1.648
Ashburn 833
The Dalles 729
San Mateo 689
Dallas 543
Ann Arbor 530
Shanghai 523
Helsinki 441
San Jose 439
Boardman 379
New York 346
Dublin 322
Leawood 310
Beijing 295
Lawrence 288
Princeton 288
Benin City 271
Ho Chi Minh City 256
Hanoi 220
Hong Kong 214
Paris 160
Woodbridge 136
Fairfield 132
Amsterdam 115
São Paulo 110
Toronto 98
Milan 96
London 78
Los Angeles 74
Seattle 74
Council Bluffs 58
Santa Clara 56
Columbus 53
San Diego 49
Orem 44
Brussels 42
Da Nang 42
Rio de Janeiro 42
Kocaeli 39
Falkenstein 38
Norwalk 33
Moscow 29
Phoenix 29
Tokyo 29
Falls Church 27
Haiphong 27
Pune 27
Curitiba 25
Belo Horizonte 24
Chennai 24
Warsaw 24
Frankfurt am Main 23
Manchester 23
Houston 21
Baghdad 20
Naples 20
Porto Alegre 20
Brooklyn 19
Rome 19
Brasília 18
Nairobi 18
Stockholm 17
Hải Dương 16
San Francisco 16
Amman 15
Boston 15
Cambridge 15
Campinas 15
Mexico City 15
Monmouth Junction 15
Assago 14
Johannesburg 14
Montreal 14
Munich 14
Salvador 14
Tashkent 14
Atlanta 13
Fortaleza 13
Buenos Aires 12
Des Moines 12
Mumbai 12
Poplar 12
Reston 12
Asyut 11
Biên Hòa 11
Chicago 11
Dhaka 11
Erbil 11
Ninh Bình 11
Recife 11
Redmond 11
Redwood City 11
Andover 10
Can Tho 10
Cape Town 10
Charlotte 10
Clearwater 10
Denver 10
Totale 16.484
Salva come PNG Salva come JPEG
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 203
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? 153
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 147
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 144
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 141
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 133
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 131
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 128
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 126
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 126
A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019 125
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 124
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 124
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 119
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 118
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 115
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 111
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 110
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 107
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 106
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 105
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 105
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 105
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 104
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 103
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 103
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 102
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 102
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 102
EASL Recommendations on Treatment of Hepatitis C 2014 102
Real life experiences in HCV management in 2018 102
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 101
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 101
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 100
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 99
Daclatasvir for the treatment of chronic hepatitis C 99
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 99
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 98
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 98
From current status to optimization of HCV treatment: Recommendations from an expert panel 97
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 97
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 96
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 96
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 96
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 95
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 95
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy 95
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients 95
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 94
Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization 94
The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment 93
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 93
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 93
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 93
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 93
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 92
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? 92
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 92
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 92
High mortality in COVID-19 patients with mild respiratory disease 92
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? 91
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 91
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 90
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 89
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 89
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 89
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 89
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 88
Mapping the human genetic architecture of COVID-19 88
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 87
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 87
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 87
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 87
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 87
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 87
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 87
Safety of vedolizumab in liver transplant recipients: A systematic review 87
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 86
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 86
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 86
An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study 85
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 85
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 85
Recommendations for the management of hepatitis C virus infection among people who inject drugs 85
Are We Ready to Discontinue Hepatitis B Immunoglobulins to Prevent Hepatitis B and D Recurrence in Liver Transplant Recipients? 85
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 84
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 84
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 84
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials 84
Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes 84
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 83
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 83
Hepatitis C treatment in patients with kidney disease 83
Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery 83
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature 83
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 83
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 82
Chronic hepatitis C: standard of care and perspective 82
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 82
Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir 82
Totale 9.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021783 0 0 0 0 0 0 0 0 0 399 13 371
2021/20221.691 79 18 59 359 20 21 77 221 121 197 405 114
2022/20234.749 675 211 459 563 430 409 7 418 877 362 273 65
2023/20242.682 184 263 549 130 103 422 149 153 38 46 250 395
2024/20253.997 118 102 51 88 96 417 286 500 551 906 459 423
2025/20269.064 1.484 628 640 876 225 408 3.173 638 560 432 0 0
Totale 25.266